Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27903439 | 0.88 | HSD11B1 (0.65) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL233562 | 0.86 | HSD11B1 (0.62) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL26851522 | 0.86 | HSD11B1 (0.66) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL2733659 | 0.84 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL3903304 | 0.82 | LMNA (0.69) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL18701802 | 0.81 | SMN1; SMN2 (0.67) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL1706076 | 0.81 | SMN1; SMN2 (0.57) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL18711414 | 0.81 | SMN1; SMN2 (0.70) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL233242 | 0.79 | HSD11B1 (0.60) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 | |
| SCHEMBL231869 | 0.79 | HSD11B1 (0.60) | MAPTALDH1A1SMN1; SMN2KDM4EHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1751108-B1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8415354-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| CN-102459159-A | Alkanoylamino benzamide aniline hdac inihibitor compounds | GILEAD COLORADO INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2440519-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1751108-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | ABBOTT LABORATORIES | 2006-07-06 | — | — | US | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | MAPT 4594/4885ALDH1A1 147/4885SMN1; SMN2 3237/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | MAPT 3569/4885ALDH1A1 188/4885SMN1; SMN2 1583/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | MAPT 3569/4885ALDH1A1 188/4885SMN1; SMN2 1583/4885 |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | MAPT 4347/4885ALDH1A1 157/4885SMN1; SMN2 3613/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | MAPT 4347/4885ALDH1A1 157/4885SMN1; SMN2 3613/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | MAPT 2031/4885ALDH1A1 339/4885SMN1; SMN2 2428/4885 |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | MAPT 4347/4885ALDH1A1 157/4885SMN1; SMN2 3613/4885 |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | HSD11B1, HSD17B1, HSD11B2 | MAPT 1948/4885ALDH1A1 54/4885SMN1; SMN2 1008/4885 |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | MAPT 4637/4885ALDH1A1 126/4885SMN1; SMN2 3167/4885 |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | MAPT 4594/4885ALDH1A1 147/4885SMN1; SMN2 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.